A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction Therapy

Inclusion Criteria

• •Participant eligibility is determined according to the following criteria prior to entry into the study:
• •In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
• •Participant either signs and dates a written, informed consent form or completes an e-consent process prior to the initiation of any study procedures.
• •Participant has been diagnosed with GD type I; diagnosis was confirmed biochemically and/or genetically.
• •Participant has been treated with SRT for at least 3 months prior to switch to VPRIV.
• •Participant has been treated with VPRIV at least 3 months prior to enrollment (Baseline \[Day 0\]).
• •Participant is aged 18 or older.
• •Arm A: Participant is able to use mobile application based on clinician's judgment, (e.g., owns an iPhone version 5 or later or smartphones with Android operating systems, have an active data plan or regular Wi-Fi access).
• •Arm A: The participant's primary language is English.